ATE503014T1 - Rna-amidate und thioamidateur rnai - Google Patents

Rna-amidate und thioamidateur rnai

Info

Publication number
ATE503014T1
ATE503014T1 AT04818592T AT04818592T ATE503014T1 AT E503014 T1 ATE503014 T1 AT E503014T1 AT 04818592 T AT04818592 T AT 04818592T AT 04818592 T AT04818592 T AT 04818592T AT E503014 T1 ATE503014 T1 AT E503014T1
Authority
AT
Austria
Prior art keywords
rna
thioamidates
amidates
thioamidateur
amidate
Prior art date
Application number
AT04818592T
Other languages
English (en)
Inventor
Sergei Gryaznov
Krisztina Pongracz
Original Assignee
Geron Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Geron Corp filed Critical Geron Corp
Application granted granted Critical
Publication of ATE503014T1 publication Critical patent/ATE503014T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/111—General methods applicable to biologically active non-coding nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1131—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against viruses
    • C12N15/1132—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against viruses against retroviridae, e.g. HIV
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/314—Phosphoramidates
    • C12N2310/3145—Phosphoramidates with the nitrogen in 3' or 5'-position
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/351—Conjugate
    • C12N2310/3515—Lipophilic moiety, e.g. cholesterol
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/50—Methods for regulating/modulating their activity
    • C12N2320/51—Methods for regulating/modulating their activity modulating the chemical stability, e.g. nuclease-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Virology (AREA)
  • AIDS & HIV (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
AT04818592T 2003-11-04 2004-11-03 Rna-amidate und thioamidateur rnai ATE503014T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US51676903P 2003-11-04 2003-11-04
PCT/US2004/032780 WO2005047506A1 (en) 2003-11-04 2004-11-03 Rna amidates and thioamidates for rnai

Publications (1)

Publication Number Publication Date
ATE503014T1 true ATE503014T1 (de) 2011-04-15

Family

ID=34590131

Family Applications (1)

Application Number Title Priority Date Filing Date
AT04818592T ATE503014T1 (de) 2003-11-04 2004-11-03 Rna-amidate und thioamidateur rnai

Country Status (7)

Country Link
US (3) US9133233B2 (de)
EP (1) EP1694842B1 (de)
AT (1) ATE503014T1 (de)
AU (1) AU2004289975B2 (de)
CA (1) CA2544349C (de)
DE (1) DE602004031975D1 (de)
WO (1) WO2005047506A1 (de)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7356912B2 (en) 2003-09-25 2008-04-15 W.E.T. Automotive Systems, Ltd. Method for ventilating a seat
DE602004031975D1 (de) * 2003-11-04 2011-05-05 Geron Corp Rna-amidate und thioamidateur rnai
RS61840B1 (sr) 2004-07-02 2021-06-30 Geron Corp Sinteza zaštićenih 3'-amino 5'-fosforamidit nukleozidnih monomera
WO2008094640A2 (en) 2007-01-30 2008-08-07 Geron Corporation Compounds having anti-adhesive effects on cancer cells
US9364495B2 (en) * 2009-10-20 2016-06-14 Roche Innovation Center Copenhagen A/S Oral delivery of therapeutically effective LNA oligonucleotides
US9375485B2 (en) 2012-12-07 2016-06-28 Geron Corporation Use of telomerase inhibitors for the treatment of myeloproliferative disorders and myeloproliferative neoplasms
EP3052512A4 (de) 2013-09-30 2017-02-22 Geron Corporation Phosphorodiamidat-rückgratverbindung für oligonukleotide
AU2017326372B2 (en) * 2016-09-14 2023-12-07 Janssen Biopharma, Inc. Modified oligonucleotides and methods of use
EP3658156B1 (de) 2017-07-28 2026-03-25 Geron Corporation Telomerase hemmer zur behandlung eines myelodysplastischen syndroms
IL273274B2 (en) * 2017-09-14 2023-12-01 Janssen Biopharma Llc Modified nucleoside phosphoramidites
CN113631719A (zh) 2018-11-29 2021-11-09 美国杰龙生物医药公司 治疗骨髓增生异常综合征的方法
US20230250125A1 (en) * 2020-04-01 2023-08-10 Janssen Biopharma, Inc. Nucleic acid polymers
WO2025207561A1 (en) * 2024-03-27 2025-10-02 Cepheid Isothermal amplification using novel synthetic oligonucleotides

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5726297A (en) 1994-03-18 1998-03-10 Lynx Therapeutics, Inc. Oligodeoxyribonucleotide N3' P5' phosphoramidates
US5599922A (en) 1994-03-18 1997-02-04 Lynx Therapeutics, Inc. Oligonucleotide N3'-P5' phosphoramidates: hybridization and nuclease resistance properties
HUT76094A (en) 1994-03-18 1997-06-30 Lynx Therapeutics Oligonucleotide n3'-p5' phosphoramidates: synthesis and compounds; hybridization and nuclease resistance properties
US20030026782A1 (en) * 1995-02-07 2003-02-06 Arthur M. Krieg Immunomodulatory oligonucleotides
US5684143A (en) 1996-02-21 1997-11-04 Lynx Therapeutics, Inc. Oligo-2'-fluoronucleotide N3'->P5' phosphoramidates
US5859233A (en) 1996-02-21 1999-01-12 Lynx Therapeutics, Inc. Synthons for synthesis of oligonucleotide N3-P5 phosphoramidates
AU776150B2 (en) 1999-01-28 2004-08-26 Medical College Of Georgia Research Institute, Inc. Composition and method for (in vivo) and (in vitro) attenuation of gene expression using double stranded RNA
DE19956568A1 (de) 1999-01-30 2000-08-17 Roland Kreutzer Verfahren und Medikament zur Hemmung der Expression eines vorgegebenen Gens
HK1049339B (en) 1999-09-10 2008-06-27 Geron Corporation Oligonucleotide n3'-p5' thiophosphoramidates: their synthesis and use
GB9927444D0 (en) 1999-11-19 2000-01-19 Cancer Res Campaign Tech Inhibiting gene expression
JP2003526367A (ja) 2000-03-16 2003-09-09 ジェネティカ インコーポレイテッド Ｒｎａ干渉の方法とｒｎａ干渉組成物
KR20080023768A (ko) 2000-03-30 2008-03-14 화이트헤드 인스티튜트 포 바이오메디칼 리서치 Ｒｎａ 간섭의 ｒｎａ 서열 특이적인 매개체
US20040019003A1 (en) * 2002-01-24 2004-01-29 Chiron Corporation Nek2 inhibitors
US7897752B2 (en) 2002-02-20 2011-03-01 Sirna Therapeutics, Inc. RNA interference mediated inhibition of telomerase gene expression using short interfering nucleic acid (siNA)
WO2003100001A2 (en) * 2002-05-20 2003-12-04 Immunex Corporation Claudin polypeptides, polynucleotides, and methods of making and use thereof
US20040014108A1 (en) * 2002-05-24 2004-01-22 Eldrup Anne B. Oligonucleotides having modified nucleoside units
WO2004003152A2 (en) * 2002-06-26 2004-01-08 Chiron Corporation Sos1 inhibitors
AU2003259735A1 (en) * 2002-08-08 2004-02-25 Sirna Therapeutics, Inc. Small-mer compositions and methods of use
AU2003277021A1 (en) * 2002-09-27 2004-04-19 Biomira, Inc. Glycosylceramide analogues
EP2000160A3 (de) * 2002-10-30 2009-03-11 Gambro Lundia AB Verfahren und Vorrichtungen zur Bestimmung der Dialyseeffizienz
WO2004062591A2 (en) * 2003-01-06 2004-07-29 Oregon Health And Science University Methods of treatment and diagnosis of kaposi's sarcoma (ks) and ks related diseases
CA2518475C (en) 2003-03-07 2014-12-23 Alnylam Pharmaceuticals, Inc. Irna agents comprising asymmetrical modifications
EP2669377A3 (de) 2003-04-17 2015-10-14 Alnylam Pharmaceuticals Inc. Modifizierte iRNA-Wirkstoffe
WO2005044976A2 (en) * 2003-06-20 2005-05-19 Isis Pharmaceuticals, Inc. Oligomeric compounds for use in gene modulation
EP1649019A2 (de) * 2003-07-15 2006-04-26 California Institute Of Technology Verbesserte inhibitor-nukleinsäuren
DK3342425T3 (da) 2003-09-09 2020-03-16 Geron Corp Modificerede oligonukleotider til inhibering af telomerase
DE602004031975D1 (de) 2003-11-04 2011-05-05 Geron Corp Rna-amidate und thioamidateur rnai
RS61840B1 (sr) 2004-07-02 2021-06-30 Geron Corp Sinteza zaštićenih 3'-amino 5'-fosforamidit nukleozidnih monomera
US9228189B2 (en) * 2012-10-26 2016-01-05 Geron Corporation C-myc antisense oligonucleotides and methods for using the same to treat cell-proliferative disorders

Also Published As

Publication number Publication date
US20160130580A1 (en) 2016-05-12
DE602004031975D1 (de) 2011-05-05
US9822360B2 (en) 2017-11-21
EP1694842A1 (de) 2006-08-30
US20070275919A1 (en) 2007-11-29
AU2004289975B2 (en) 2011-11-03
US20180119147A1 (en) 2018-05-03
US10655127B2 (en) 2020-05-19
CA2544349C (en) 2020-02-18
AU2004289975A1 (en) 2005-05-26
US9133233B2 (en) 2015-09-15
CA2544349A1 (en) 2005-05-26
EP1694842B1 (de) 2011-03-23
WO2005047506A1 (en) 2005-05-26

Similar Documents

Publication Publication Date Title
DE602004031975D1 (de) Rna-amidate und thioamidateur rnai
WO2005007196A3 (en) Lipid encapsulated interfering rna
WO2006113679A3 (en) Delivery of sirna by neutral lipid compositions
EP1766035A4 (de) Lipidverkapselte interferenz-rna
MX2022013691A (es) Formulaciones que contienen lipidos.
ATE534737T1 (de) Gezielte abgabe von sirna
MX2007004321A (es) Micro acidos ribonucleicos.
CY1112420T1 (el) Ρυθμιση της γονιδιακης εκφρασης στα φυτα με μεσολαβηση dsrνα
WO2014127287A8 (en) Method for in vivo targeted mutagenesis
EP3034083A3 (de) Antisense-oligonukleotide zur behandlung von myotoner dystrophie
WO2006138572A3 (en) Conjugates having a degradable linkage and polymeric reagents useful in preparing such conjugates
NZ596958A (en) Improved lipid formulation
EP2304026A4 (de) Nanopartikelzusammensetzungen für ein system zur ausgabe von nukleinsäuren
AR069821A1 (es) Composiciones y metodos de uso de la interferencia de arn para el control de nematodos
WO2006036916A3 (en) Rnai modulation of apob and uses thereof
WO2010057150A8 (en) Releasable polymeric lipids for nucleic acids delivery system
WO2008131419A3 (en) Glycoconjugates of rna interference agents
ES2926369T3 (es) Molécula de ácido nucleico monocatenario que tiene función de suministro y capacidad de control de la expresión génica
AU2014219019A8 (en) Short interfering nucleic acid (siNA) molecules containing a 2' internucleoside linkage
ATE479752T1 (de) Therapeutische zusammensetzungen
WO2008094640A3 (en) Compounds having anti-adhesive effects on cancer cells
WO2019147308A3 (en) Rna nanostructures and methods of making and using rna nanostructures
MX2024011671A (es) Oligonucleotidos modificados
WO2007014075A3 (en) Rnai modulation of the rho-a gene in research models
Su et al. Neutral and negatively charged phosphate modifications altering thermal stability, kinetics of formation and monovalent ion dependence of DNA G‐Quadruplexes

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties